karolina.strzebonska@uj.edu.pl

Assistant professor in the Chair of Bioethics and Health Psychology.

Winner of START 2021, stipend program for early-career researchers, Foundation for Polish Science.

Member of REMEDY. Since 2019 member of Cochrane.  

In May 2020 Strzebonska received grant from National Science Center ‘Ethics of research with human subjects in precision medicine’. 

https://www.ncn.gov.pl/sites/default/files/listy-rankingowe/2019-09-16/streszczenia/464084-en.pdf 

A graduate of the AGH University of Science and Technology. Spent four months on a research placement in a laboratory at i3S – Institute of Health Innovation and Research in Porto. Graduate in Bioethics, University of Warsaw, Institute of Philosophy.

Her main interests are: research ethics, evidence-based medicine, basket and umbrella clinical trial designs. Her doctoral thesis concerned risk-benefit assessment in clinical trials in oncology. 

 Publications:

• Nilsonne G, Wieschowski S, DeVito NJ, Salholz-Hillel M, Bruckner T, Klas K, et al. (2025). Results reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed. Journal of Clinical Epidemiology https://doi.org/10.1016/j.jclinepi.2025.111710
• Klas K, Strzebonska K, Buedo P, Włodarczyk A, Gordon S, et al. (2024) Seamless trials in oncology: A cross-sectional analysis of characteristics and reporting. PLOS ONE 19(12): e0312797. https://doi.org/10.1371/journal.pone.0312797
• Klas K, Strzebonska K, Waligora M. Ethical challenges of clinical trials with a repurposed drug in outbreaks Med Health Care and Philos (2023). doi.org/10.1007/s11019-023-10140-4
• Strzebonska K, Blukacz M, Wasylewski MT, Polak M, Gyawali B, Waligora M. Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. BMC Med. 2022; 20:219. doi: 10.1186/s12916-022-02420-2
• Strzebonska K, Wasylewski MT, Zaborowska L, Polak M, Slugocka E, Stras J, Blukacz M, Gyawali B, Waligora M. Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis. Target Oncol. 2021; 16(4):415-424. doi:10.1007/s11523-021-00822-5
• Wasylewski MT, Strzebonska K, Koperny M, Polak M, Kimmelman J, Waligora M (2020), Clinical development success rates and social value of pediatric Phase 1 trials in oncology, PLoS ONE 15(6): e0234911. doi: 10.1371/journal.pone.0234911
• Strzebonska K, Wasylewski MT, Zaborowska L, Riedel N, Wieschowski S, Strech D, et al. Results dissemination of registered clinical trials across Polish academic institutions: a cross-sectional analysis. BMJ Open, 2020;10:e034666. doi: 10.1136/bmjopen-2019-034666
• Strzebonska K, Waligora M. Umbrella and basket trials in oncology: ethical challenges. BMC Medical Ethics, 2019; 20:1-10. doi: https://doi.org/10.1186/s12910-019-0395-5 
• Strzebonska K, Waligora M. Underestimation of Harms in Phase I Trials. The Journal of Law, Medicine & Ethics, 2019; 47:334-335. doi: 10.1177/1073110519857290
• Waligora M, Bala MM, Koperny M, Wasylewski MT, Strzebonska K, Jaeschke RR, Wozniak A, Piasecki J, Sliwka A, Mitus JW, Polak M, Nowis D, Fergusson D, Kimmelman J. Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis. PLOS Medicine, 2018; 15:e1002505. doi: 10.1371/journal.pmed.1002505
• Waligora M, Strzebonska K, Wasylewski MT. Neither the harm principle nor the best interest standard should be applied to pediatric research. The American Journal of Bioethics, 2018; 18:72-74. doi: 10.1080/15265161.2018.1485762
• Zhang Y, Morgan RL, Alonso-Coello P, Wiercioch W, Bała MM, Jaeschke RR, Styczeń K, Pardo-Hernandez H, Selva A, Begum HA, Morgano GP, Waligóra M, Agarwal A, Ventresca M, Strzebońska K, Wasylewski MT, Blanco-Silvente L, Kerth JL, Wang M, Zhang Y, Narsingam S, Fei Y, Guyatt G, Schünemann HJ. A systematic review of how patients value COPD outcomes. European Respiratory Journal, 2018; 52: 1800222. doi: 10.1183/13993003.00222-2018